Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Tax withholdingCommon Stock | 199 | $74.73 | $14,871.27 |
DisclosureSEC source: 0001225208-26-002137 · doc4.xml · nonDerivative · entry 2 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,787 Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Exercise / conversionCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002137 · doc4.xml · nonDerivative · entry 1 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionRestricted Stock Units · Derivative | 1,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002139 · doc4.xml · derivative · entry 7 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,239 Underlying: Common Stock · 1,413 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Tax withholdingCommon Stock | 690 | $74.73 | $51,563.70 |
DisclosureSEC source: 0001225208-26-002139 · doc4.xml · nonDerivative · entry 2 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,674 Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 1,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002139 · doc4.xml · nonDerivative · entry 1 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Monson JonathanEVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 1,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002136 · doc4.xml · derivative · entry 7 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 1,766 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Monson JonathanEVP and CFO
|
Tax withholdingCommon Stock | 788 | $74.73 | $58,887.24 |
DisclosureSEC source: 0001225208-26-002136 · doc4.xml · nonDerivative · entry 2 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,848 Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Monson JonathanEVP and CFO
|
Exercise / conversionCommon Stock | 1,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002136 · doc4.xml · nonDerivative · entry 1 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002138 · doc4.xml · derivative · entry 8 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,767 Underlying: Common Stock · 588 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Tax withholdingCommon Stock | 200 | $74.73 | $14,946.00 |
DisclosureSEC source: 0001225208-26-002138 · doc4.xml · nonDerivative · entry 2 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,808 Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002138 · doc4.xml · nonDerivative · entry 1 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 8,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · derivative · entry 10 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,498 Underlying: Common Stock · 8,832 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 132,099 | $74.73 | $9,871,758.27 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,559,926 Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 8,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,692,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantCommon Stock | 132,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,683,193 F2 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantCommon Stock | 132,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,551,003 F1 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionRestricted Stock Units · Derivative | 2,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · derivative · entry 10 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,713 Underlying: Common Stock · 2,237 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Tax withholdingCommon Stock | 25,150 | $74.73 | $1,879,459.50 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · nonDerivative · entry 4 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,837 Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionCommon Stock | 2,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · nonDerivative · entry 3 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
GrantCommon Stock | 25,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,750 F2 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
GrantCommon Stock | 25,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,370 F1 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionRestricted Stock Units · Derivative | 2,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · derivative · entry 10 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,391 Underlying: Common Stock · 2,797 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 33,104 | $74.73 | $2,473,861.92 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,381 Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionCommon Stock | 2,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
GrantCommon Stock | 34,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,688 F2 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
GrantCommon Stock | 34,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,790 F1 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 1,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · derivative · entry 9 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,357 Underlying: Common Stock · 1,118 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 12,792 | $74.73 | $955,946.16 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 4 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,339 Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 1,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 3 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
GrantCommon Stock | 14,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,013 F2 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
GrantCommon Stock | 14,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,209 F1 · kind: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:09 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 11,143 | $0.00 Strike: $74.12 | $0.00 |
DisclosureSEC source: 0001225208-26-002021 · doc4.xml · derivative · entry 6 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,143 Underlying: Common Stock · 11,143 shares Expires 2036-02-12 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:09 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
GrantRestricted Stock Units · Derivative | 4,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002021 · doc4.xml · derivative · entry 5 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,722 Underlying: Common Stock · 4,722 shares Expires 2030-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:09 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 961 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002021 · doc4.xml · derivative · entry 4 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,924 Underlying: Common Stock · 961 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:09 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Tax withholdingCommon Stock | 338 | $74.12 | $25,052.56 |
DisclosureSEC source: 0001225208-26-002021 · doc4.xml · nonDerivative · entry 2 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,420 Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:09 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 961 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002021 · doc4.xml · nonDerivative · entry 1 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:07 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
GrantStock Option (Right to Buy) · Derivative | 5,584 | $0.00 Strike: $74.12 | $0.00 |
DisclosureSEC source: 0001225208-26-002020 · doc4.xml · derivative · entry 5 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,584 Underlying: Common Stock · 5,584 shares Expires 2036-02-12 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:07 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
GrantRestricted Stock Units · Derivative | 6,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002020 · doc4.xml · derivative · entry 4 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,071 Underlying: Common Stock · 6,071 shares Expires 2030-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:07 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionRestricted Stock Units · Derivative | 481 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002020 · doc4.xml · derivative · entry 3 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 962 Underlying: Common Stock · 481 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:07 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Tax withholdingCommon Stock | 242 | $74.12 | $17,937.04 |
DisclosureSEC source: 0001225208-26-002020 · doc4.xml · nonDerivative · entry 2 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 951 Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:07 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 481 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002020 · doc4.xml · nonDerivative · entry 1 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired on June 30, 2025 under the Company's Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:07 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
GrantStock Option (Right to Buy) · Derivative | 11,939 | $0.00 Strike: $74.12 | $0.00 |
DisclosureSEC source: 0001225208-26-002018 · doc4.xml · derivative · entry 5 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,939 Underlying: Common Stock · 11,939 shares Expires 2036-02-12 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:07 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
GrantRestricted Stock Units · Derivative | 5,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002018 · doc4.xml · derivative · entry 4 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,059 Underlying: Common Stock · 5,059 shares Expires 2030-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:07 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 1,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002018 · doc4.xml · derivative · entry 3 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,116 Underlying: Common Stock · 1,058 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:07 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Tax withholdingCommon Stock | 457 | $74.12 | $33,872.84 |
DisclosureSEC source: 0001225208-26-002018 · doc4.xml · nonDerivative · entry 2 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,486 Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:07 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Exercise / conversionCommon Stock | 1,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002018 · doc4.xml · nonDerivative · entry 1 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:06 UTC |
Monson JonathanEVP and CFO
|
GrantStock Option (Right to Buy) · Derivative | 27,857 | $0.00 Strike: $74.12 | $0.00 |
DisclosureSEC source: 0001225208-26-002017 · doc4.xml · derivative · entry 5 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,857 Underlying: Common Stock · 27,857 shares Expires 2036-02-12 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:06 UTC |
Monson JonathanEVP and CFO
|
GrantRestricted Stock Units · Derivative | 11,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002017 · doc4.xml · derivative · entry 4 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,805 Underlying: Common Stock · 11,805 shares Expires 2030-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:06 UTC |
Monson JonathanEVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 1,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002017 · doc4.xml · derivative · entry 3 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,308 Underlying: Common Stock · 1,154 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:06 UTC |
Monson JonathanEVP and CFO
|
Tax withholdingCommon Stock | 573 | $74.12 | $42,470.76 |
DisclosureSEC source: 0001225208-26-002017 · doc4.xml · nonDerivative · entry 2 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,870 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.